Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab

Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment

Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.